Trials / Completed
CompletedNCT04883775
Study of a New Technique for Imaging Pancreatic Cancer
89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MVT-2163 | MVT-2163 is administered intravenously as a PET imaging agent. |
| DRUG | MVT-5873 | MVT-5873 will be administered intravenously over at least 60 minutes. |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2025-01-27
- Completion
- 2025-01-27
- First posted
- 2021-05-12
- Last updated
- 2025-01-30
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04883775. Inclusion in this directory is not an endorsement.